
Barclays raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $14 and keeps an Overweight rating on the shares. The company’s “impressive” Q3 was driven by Recorlev,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| XERS | Xeris Pharmaceuticals | 16.70 | 9.42 | 129.48% |
| Name | Price | % Change | |
|---|---|---|---|
| $16.70 | +129.48% |

Barclays raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $14 and keeps an Overweight rating on the shares. The company’s “impressive” Q3 was driven by Recorlev,

Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $12 and keeps a Buy rating on the shares. Xeris reported a very impressive

Oppenheimer raised the firm’s price target on Xeris Biopharma (XERS) to $21 from $18 and keeps an Outperform rating on the shares following quarterly results. The firm views record Recorlev

Piper Sandler raised the firm’s price target on Xeris Biopharma (XERS) to $12 from $8 and keeps a Neutral rating on the shares following quarterly results. Management is now guiding

H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $10 and keeps a Buy rating on the shares. The company’s Q3 results

Xeris Pharmaceuticals (($XERS)) has held its Q3 earnings call. Read on for the main highlights of the call. Xeris Pharmaceuticals delivered a strongly positive earnings call, highlighted by record third-quarter

The major averages were sharply lower following yesterday’s broad gains, with the Dow and Nasdaq both falling over 1,000 points, as traders appear to be rotating away from technology names

Reports Q3 revenue $107M, consensus $101.68M. “As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating

John Shannon, Chairman and Chief Executive Officer of Xeris said, “We also continued to advance XP-8121 following our comprehensive program overview in September. We remain on track to initiate Cornerstone,

Raises 2030 total revenue outlook to more than $1B, up from approximately $750M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 10, 2027TBA | $3.04B | $0.07 | $119.03M | -22.22 | -415.46 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.